Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Opts to Close Microarray Business; Will Axe 20 Percent of Staff and Focus on RT-PCR

NEW YORK (GenomeWeb News) - Nanogen has ended two months of speculation about the future of its microarray business by saying it decided to shut down the unit, lay off around 20 percent of its staff, and realign the company behind its real-time PCR and point-of-care testing units, the firm said Monday.
 
As GenomeWeb Daily News reported in September, the company had hired investment banking firm Credit Suisse to help it explore strategic options for the array business, which could have included selling the segment, finding a partner, or simply closing down operations.
 
“Our analysis of alternatives for the array business has not resulted in any financially meaningful opportunities” David Ludvigson, Nanogen’s president and COO, said in a statement.
 
Ludvigson projected that shedding the microarray business from its books would lower its operating expenses by around $15 million per year.
 
Earlier this week, Nanogen had said in its third-quarter earnings report that an 11-percent revenue jump was offset by expenses and restructuring costs, although it projected annual growth of 25 percent in fiscal 2008 over the current year.
 
“The future of our company and our mission to be a leading diagnostics company has not changed with this decision,” Nanogen CEO Howard Birndorf said in the statement.
 
Nanogen expects to take on a fourth-quarter charge of around $2.5 million from employee severance costs related to the closure of the microarray business.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more